Celsion To Report Clinical Trial Update Of ThermoDox(R) In Recurrent Chest Wall Breast Cancer Study

News — By on February 24, 2009 at 8:00 am

Celsion Corporation (NASDAQ: CLSN) today announced that clinical data from its ThermoDox® Phase 1 Recurrent Chest Wall (RCW) Breast Cancer study will be presented by Duke University Medical Center researchers at the Society for Thermal Medicine 2009 Annual Meeting in Tucson, Arizona on April 3-7, 2009.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback